1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top




Charting the Future Prostate Cancer Market Landscape

The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new novel therapies. The launch of Zytiga (abiraterone acetate), Medivation/Astellas’ Xtandi (enzalutamide) and Algeta/Bayer’s Xofigo are set to trigger the global prostate cancer market to grow from $3.5 billion in 2012 to $7.7 billion in 2017.


Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top analyses the global prostate cancer market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:


An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
•Timely event-driven market forecast report and data analysis updates over the next 12 months








Report Benefits:

Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top will allow you to:
Evaluate future sales forecasts and anticipated market growth

Map your market parameters and chart commercial prospects

Assess market share by company and product

Tailor your strategic and investment focus based on the competition

Set proactive launch and branding strategies

Keep up with event-driven market data updates


Forecast analysis report
The forecast analysis report component of Consensus Outlook: Prostate Cancer delivers a rich analysis of product-level sales forecast data and of the future events that underpin these forecasts. The product of meticulous FirstWord research, the report’s historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Prostate Cancer – Competition intensifies in race to the top combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed by research of analysts who have an unrivalled level of intimacy with the market, the players, their products, and their stratgies. Key features include:

Report features:


Historical prostate cancer sales from 2007–2012
Forecast prostate cancer sales from 2013-2017
Key competitors and drug developers
Anticipated product positioning
Current and late-stage pipeline drugs
Future event mapping to forecast data points
Comparative clinical trial results


Forecast data model

FirstWord’s Prostate Cancer forecast data model allows you to examine detailed Excel spreadsheets to quickly compare various market parameters including:

Market size
Product sales
Company forecasts/BulletPoint>
Company, brand, and drug class
Mechanism of action
Future events


Event-driven forecasts
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.


Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.


Methodology
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.



Table Of Contents

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
1. FirstWord Analysis Highlights
2.Research Methodology
3.Prostate Cancer Marketplace
4.Key Prostate Cancer Developers
5.Prostate Cancer Class Dynamics
6.Zytiga (abiraterone acetate; Johnson and Johnson) forecast
7.Xtandi (enzalutamide; Medivation/Astellas) forecast
8.Xofigo (radium-223 dichloride; Algeta/Bayer) forecast
9.Taxotere (docetaxel; Sanofi) forecast
10.Jevtana (cabazitaxel; Sanofi) forecast
11.Provenge (sipuleucel-T; Dendreon) forecast
12.Casodex (bicalutamide; AstraZeneca) forecast
13.Lupron (leuprolide acetate; Takeda/Abbvie) forecast
14.Bone metastases therapies forecast
15.Pipeline therapy forecasts

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Treatment Drugs Markets in China

Prostate Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • March 2016
  • by Asia Market Information & Development Company

China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Prostate Cancer Drug Pipeline Update

Prostate Cancer Drug Pipeline Update

  • $ 3 375
  • Industry report
  • February 2016
  • by Bioseeker

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various ...

Prostate Cancer Drug Pathway Analyzer

Prostate Cancer Drug Pathway Analyzer

  • $ 3 375
  • Industry report
  • February 2016
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 493 targeted molecular therapies known to affect more than 255 specific intracellular signaling pathways ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description

  • May 2016
    30 pages
  • Cancer  

    Eye Disease  

    Ophthalmology  

  • Israel  

    United States  

    China  

View report >

Pathology Description in the US

  • April 2016
    18 pages
  • Cancer  

    Prostate Cancer  

  • United States  

View report >

Pathology Description in Canada

  • April 2016
    10 pages
  • Prostate Cancer  

    Cancer  

  • Canada  

    North America  

    United States  

View report >

Pathology Description

1 month ago

Related Market Segments :

Prostate Cancer

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.